Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions.

adherence adverse reactions amiodarone monitoring

Journal

Health services research and managerial epidemiology
ISSN: 2333-3928
Titre abrégé: Health Serv Res Manag Epidemiol
Pays: United States
ID NLM: 101654536

Informations de publication

Date de publication:
Historique:
received: 17 03 2018
accepted: 18 03 2019
entrez: 27 4 2019
pubmed: 27 4 2019
medline: 27 4 2019
Statut: epublish

Résumé

Amiodarone treatment frequently causes adverse reactions. Clinical guidelines warrant a comprehensive assessment prior to chronic treatment with amiodarone and repeated monitoring for the appearance of adverse reactions. To evaluate adherence to these guidelines. A retrospective chart review of electronic medical records of adult patients treated with oral amiodarone for at least 12 months. One hundred patient records were analyzed; 97% of patients were evaluated for thyroid and liver functions prior to treatment. Liver functions were properly monitored every 6 months in 96% of patients and thyroid function in only 59%. Most (84%) patients completed a chest X-ray before treatment; only 2% completed a respiratory function test. None have performed a chest X-ray annually. Sixty-four percent of the patients were examined by an ophthalmologist prior to treatment; periodic ophthalmic surveillance was not consistent. Neurological and dermatological evaluations were not recorded for any of the patients, unless symptoms appeared. Only 50% were adherent to annual cardiac reassessment. Adherence to recommended clinical guidelines for monitoring amiodarone adverse reactions is poor. Interventions to improve compliance with these guidelines are needed.

Sections du résumé

BACKGROUND BACKGROUND
Amiodarone treatment frequently causes adverse reactions. Clinical guidelines warrant a comprehensive assessment prior to chronic treatment with amiodarone and repeated monitoring for the appearance of adverse reactions.
OBJECTIVE OBJECTIVE
To evaluate adherence to these guidelines.
METHODS METHODS
A retrospective chart review of electronic medical records of adult patients treated with oral amiodarone for at least 12 months.
RESULTS RESULTS
One hundred patient records were analyzed; 97% of patients were evaluated for thyroid and liver functions prior to treatment. Liver functions were properly monitored every 6 months in 96% of patients and thyroid function in only 59%. Most (84%) patients completed a chest X-ray before treatment; only 2% completed a respiratory function test. None have performed a chest X-ray annually. Sixty-four percent of the patients were examined by an ophthalmologist prior to treatment; periodic ophthalmic surveillance was not consistent. Neurological and dermatological evaluations were not recorded for any of the patients, unless symptoms appeared. Only 50% were adherent to annual cardiac reassessment.
CONCLUSIONS CONCLUSIONS
Adherence to recommended clinical guidelines for monitoring amiodarone adverse reactions is poor. Interventions to improve compliance with these guidelines are needed.

Identifiants

pubmed: 31024983
doi: 10.1177/2333392819844635
pii: 10.1177_2333392819844635
pmc: PMC6472159
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2333392819844635

Déclaration de conflit d'intérêts

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Am J Ophthalmol. 1999 May;127(5):610-2
pubmed: 10334361
Circulation. 1999 Nov 9;100(19):2025-34
pubmed: 10556230
J Cardiovasc Electrophysiol. 2000 Jul;11(7):736-40
pubmed: 10921789
Arch Intern Med. 2001 Mar 12;161(5):649-55
pubmed: 11231696
Am J Cardiol. 2002 Nov 1;90(9):964-8
pubmed: 12398963
Am Fam Physician. 2003 Dec 1;68(11):2189-96
pubmed: 14677664
Medicine (Baltimore). 2004 Mar;83(2):107-13
pubmed: 15028964
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
Intern Med J. 2006 May;36(5):289-93
pubmed: 16650193
Heart Rhythm. 2007 Sep;4(9):1250-9
pubmed: 17765636
JAMA. 2007 Sep 19;298(11):1312-22
pubmed: 17878423
Am J Med. 2007 Oct;120(10):880-5
pubmed: 17904459
Can Respir J. 2008 Oct;15(7):370-4
pubmed: 18949107
Arch Bronconeumol. 2016 Jan;52(1):24-8
pubmed: 25912937
Cost Eff Resour Alloc. 2015 Sep 12;13:15
pubmed: 26366122
Ophthalmology. 2015 Dec;122(12):2553-9
pubmed: 26391464
J Eval Clin Pract. 2017 Feb;23(1):108-113
pubmed: 27515316
Hepatology. 1989 May;9(5):679-85
pubmed: 2785079
Cardiovasc Ther. 2017 Jun;35(3):null
pubmed: 28276175
BMJ Glob Health. 2016 Sep 28;1(2):e000064
pubmed: 28588939
Am J Med. 1989 Jan;86(1):4-10
pubmed: 2910095
J Med Internet Res. 2018 Dec 18;20(12):e294
pubmed: 30563822
Chest. 1988 May;93(5):1067-75
pubmed: 3282816
Am Heart J. 1983 Oct;106(4 Pt 2):902-5
pubmed: 6613837
Circulation. 1995 Dec 1;92(11):3264-72
pubmed: 7586313
Ann Pharmacother. 1995 Jun;29(6):582-6
pubmed: 7663029
Ann Intern Med. 1994 Oct 1;121(7):529-35
pubmed: 8067651
Doc Ophthalmol. 1993;83(4):323-9
pubmed: 8223102
Ann Intern Med. 1997 Aug 15;127(4):294-303
pubmed: 9265430
J Am Coll Cardiol. 1997 Sep;30(3):791-8
pubmed: 9283542
Surv Ophthalmol. 1998 Jan-Feb;42(4):360-6
pubmed: 9493278
J Am Coll Cardiol. 1998 Jun;31(7):1672-8
pubmed: 9626850

Auteurs

Ophir Lavon (O)

Clinical Pharmacology and Toxicology Unit, Carmel Medical Center, Haifa, Israel.
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Ron Goldman (R)

Clinical Pharmacology and Toxicology Unit, Carmel Medical Center, Haifa, Israel.

Classifications MeSH